Jan-Olaf Gebbers
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
Navarini A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker L, Heijnen I, Daikeler T, Gebbers J, Grimbacher B, Sansom D, Jeker R, Hess C, Jauch A, Kistner A, Bigler M, Hruz P, Berger C, Hou T, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg S, Kämpe O, Burgener A, Marquardsen F, Baldin F, Recher M. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. J Allergy Clin Immunol 2016; 139:1043-1046.e5.
28.11.2016Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
28.11.2016J Allergy Clin Immunol 2016; 139:1043-1046.e5
Navarini Alexander A, Bignucolo Olivier, Meyer Benedikt, Meienberg Fabian, Mehling Matthias, Jeker Lukas T, Heijnen Ingmar, Daikeler Thomas D, Gebbers Jan-Olaf, Grimbacher Bodo, Sansom David M, Jeker Raphael, Hess Christoph, Jauch Annaise, Kistner Anne, Bigler Marc, Hruz Petr, Berger Christoph T, Hou Tie Zheng, Schwab Charlotte, Gabrysch Annemarie, Higgins Rebecca, Frede Natalie, Padberg Sgier, Kämpe Olle, Burgener Anne-Valérie, Marquardsen Florian, Baldin Fabian, Recher Mike
Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer
Truninger K, Jiricny J, Schär P, Heinimann K, Cattaruzza M, Riehle H, Neuweiler J, Yurtsever H, Bannwart F, Gebbers J, Haider R, Russell A, Luz J, Menigatti M, Marra G. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005; 128:1160-71.
01.05.2005Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer
01.05.2005Gastroenterology 2005; 128:1160-71
Truninger Kaspar, Jiricny Josef, Schär Primo, Heinimann Karl, Cattaruzza Maria Sofia, Riehle Hans-Martin, Neuweiler Jörg, Yurtsever Hueseyin, Bannwart Fridolin, Gebbers Jan-Olaf, Haider Ritva, Russell Anna, Luz Judith, Menigatti Mirco, Marra Giancarlo